Evaluation of cell death mechanisms induced by the vascular disrupting agent OXi4503 during a phase I clinical trial

被引：0
|
作者：
J Cummings
M Zweifel
N Smith
P Ross
J Peters
G Rustin
P Price
M R Middleton
T Ward
C Dive
机构：
[1] Clinical and Experimental Pharmacology Group,Department of Medical Oncology
[2] Manchester Cancer Research Centre,Academic Department of Radiation Oncology
[3] Paterson Institute for Cancer Research,University of Oxford Department of Medical Oncology
[4] University of Manchester,undefined
[5] Manchester,undefined
[6] Mount Vernon Cancer Centre,undefined
[7] Middlesex,undefined
[8] Northwood HA6 2RN,undefined
[9] UK,undefined
[10] Drug Development Office,undefined
[11] Cancer Research UK,undefined
[12] 61 Lincoln's Inn Fields,undefined
[13] London WC2A 3PX,undefined
[14] UK,undefined
[15] University of Manchester,undefined
[16] The Christie NHS Foundation Trust,undefined
[17] Oxford Biomedical Research Centre Cancer Theme,undefined
[18] Churchill Hospital,undefined
来源：
British Journal of Cancer | 2012年 / 106卷
关键词：
OXi4503; vascular disrupting agent; phase I trial; cell death mechanisms; M30 ELISA; M65 ELISA;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1766 / 1771
页数：5
相关论文
共 50 条
  • [1] Evaluation of cell death mechanisms induced by the vascular disrupting agent OXi4503 during a phase I clinical trial
    Cummings, J.
    Zweifel, M.
    Smith, N.
    Ross, P.
    Peters, J.
    Rustin, G.
    Price, P.
    Middleton, M. R.
    Ward, T.
    Dive, C.
    [J]. BRITISH JOURNAL OF CANCER, 2012, 106 (11) : 1766 - 1771
  • [2] Phase I evaluation of vascular disrupting agent OXi4503
    Patterson, D. M.
    Charnley, N.
    Saleem, A.
    Stratford, M.
    Dickinson, C.
    Asselin, M.
    Ross, P.
    Walicke, P.
    Price, P.
    Rustin, G. J.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [3] Interim results from a phase I trial of the vascular disrupting agent OXi4503
    Patterson, Daniel M.
    Ross, Phillip
    Koetz, Barbara
    Saleem, Azeem
    Stratford, Mike
    Stirling, James
    Padhani, Anwar
    Asselin, Marie-Claude
    Price, Pat
    Rustin, Gordon J.
    [J]. MOLECULAR CANCER THERAPEUTICS, 2007, 6 (12) : 3436S - 3436S
  • [4] Phase I evaluation of OXi4503, a vascular disrupting agent, in patients with advanced solid tumours
    Patterson, D. M.
    Ross, P.
    Koetz, B.
    Saleem, A.
    Stratford, M.
    Stirling, J.
    Padhani, A.
    Asselin, M.
    Price, P.
    Rustin, G. J.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [5] Phase I Clinical and Pharmacokinetic Evaluation of the Vascular-Disrupting Agent OXi4503 in Patients with Advanced Solid Tumors
    Patterson, Dan M.
    Zweifel, Martin
    Middleton, Mark R.
    Price, Patricia M.
    Folkes, Lisa K.
    Stratford, Michael R. L.
    Ross, Phil
    Halford, Sarah
    Peters, Jane
    Balkissoon, Jai
    Chaplin, Dai J.
    Padhani, Anwar R.
    Rustin, Gordon J. S.
    [J]. CLINICAL CANCER RESEARCH, 2012, 18 (05) : 1415 - 1425
  • [6] The Vascular Disrupting Agent OXi4503 in Relapsed and Refractory AML and MDS
    Stockton, Shannon Somer
    Pettiford, Leslie
    Cline, Christina
    Chaplin, David
    Hsu, Jack W.
    Wingard, John R.
    Cogle, Christopher R.
    [J]. BLOOD, 2015, 126 (23)
  • [7] Enhancing stereotactic radiation schedules using the vascular disrupting agent OXi4503
    Horsman, M. R.
    Wittenborn, T. R.
    [J]. RADIOTHERAPY AND ONCOLOGY, 2016, 119 : S107 - S107
  • [8] Effect of the second-generation vascular disrupting agent OXi4503 on tumor vascularity
    Salmon, Howard W.
    Siemann, Dietmar W.
    [J]. CLINICAL CANCER RESEARCH, 2006, 12 (13) : 4090 - 4094
  • [9] Preclinical Activity of the Vascular Disrupting Agent OXi4503 against Head and Neck Cancer
    Bothwell, Katelyn D.
    Folaron, Margaret
    Seshadri, Mukund
    [J]. CANCERS, 2016, 8 (01)
  • [10] Therapeutic potential of using the vascular disrupting agent OXi4503 to enhance mild temperature thermoradiation
    Horsman, Michael R.
    [J]. INTERNATIONAL JOURNAL OF HYPERTHERMIA, 2015, 31 (05) : 453 - 459
12345